Skip to main content
SpringerLink
Log in

Anti-PD-(L)1-sotorasib sequence: high risk of hepatotoxicity

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Chour A, et al. Severe sotorasib-related hepatotoxicity and non-liver adverse events associated with sequential anti-PD(L)1 and sotorasib therapy in KRAS(G12C)-mutant lung cancer. Journal of Thoracic Oncology : 20 May 2023. Available from: URL: http://doi.org/10.1016/j.jtho.2023.05.013

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Anti-PD-(L)1-sotorasib sequence: high risk of hepatotoxicity. Reactions Weekly 1959, 8 (2023). https://doi.org/10.1007/s40278-023-40180-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-40180-z

Search

Navigation